BIHi005-A-5
General
Cell Line |
|
| hPSCreg name | BIHi005-A-5 |
| Cite as: | BIHi005-A-5 (RRID:CVCL_UW20) |
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
BIHi049-A (SCVI-112) BIONi010-C-2 (BIONi010-C ApoE E3/E3 #H8 P32) BIONi010-C-3 (BIONi010-C ApoE KO #KO30 P30) BIONi010-C-25 (BIONi010-C heterozygous TREM2 KO) BIONi010-C-6 (BIONi010-C ApoE E2/E2) BIONi010-C-7 (BIONi010-C Trem2 R47H) BIONi010-C-8 (BIONi010-C Trem2 T66M, #Y5-80) BIONi010-C-9 (BIONi010-C CD33 KO) BIONi010-C-17 (BIONi010-C TREM2 KO) BIONi010-C-70 (BIONi010-C with an APOE 2/2 genotype with an additional, homozygous christchurch mutation) BIONi010-C-71 (BIONi010-C with an APOE 3/3 genotype with an additional, homozygous christchurch mutation) BIONi010-C-4 (BIONi010-C ApoE E4/E4 #B44 P27) BIONi010-C-5 (BIONi010-C CD33 E2del #N14 P26) UCSFi001-A-74 (FUS-P525L HET 2D1) UCSFi001-A-75 (FUS-P525L HOM 2D2) WTSIi018-B-21 (Kolf 2.1 J (TARDBP M337V SNV/SNV)) WTSIi018-B-22 (Kolf 2.1 J (TARDBP Q331K WT/SNV)) WTSIi018-B-23 (Kolf 2.1 J (TARDBP Q331K SNV/SNV)) WTSIi018-B-24 (Kolf 2.1 J (FUS R495X WT/SNV)) WTSIi018-B-25 (Kolf 2.1 J (FUS R495X SNV/SNV)) WTSIi018-B-26 (Kolf 2.1 J (FUS R521H WT/SNV)) WTSIi018-B-27 (Kolf 2.1 J (FUS R521H SNV/SNV)) WTSIi018-B-18 (Kolf 2.1 J (TARDBP M337V WT/SNV)) CBIGi001-A-1 (PRKN-KO, PRKN-KO/AIW002-02) WAe001-A-76 (H1-RNF1-/-) CBIGi001-A-2 (PINK1-KO, PINK1-KO/AIW002-02) CBIGi001-A-3 (PINK1-KO/PRKN-KO/AIW002-02, PINK1-KO/PRKN-KO) UQi001-A-1 (C11-TDP43-A382T) UCSFi001-A-72 (FUS-R521G HET 2B10, LSUHSi004-A-72) UCSFi001-A-73 (FUS-R521G HOM 1D9) |
| Last update | 22nd May 2019 |
| Notes | SORL1 KO in BIHi005-A |
| User feedback | |
Provider |
|
| Generator | Berlin Institute of Health (BIH) |
| Derivation country | Germany |
External Databases |
|
| BioSamples | SAMEA1009819 |
| Cellosaurus | CVCL_UW20 |
| Wikidata | Q93426476 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | asian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Family history | Mutation in the LMNA gene in other family members but not in this sample frame shift mutation in the LMNA gene that leads to the early termination of translation (c. 349_350insG; p. K117fs) |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
| All cell lines of this donor's relatives |
Has brother:
|
External Databases (Donor) |
|
| BioSamples | SAMEA104012190 |
Ethics
Also have a look at the ethics information for the parental line
BIHi005-A
.
| Alternatives to consent | |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
BIHi005-A.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
Immunostaining
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Medium |
Essential 8™
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| SOX2 |
Yes |
|
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
Other Genotyping (Cell Line) |
Genetic Modification
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.